What sets this apart from every other fat loss approach Ive tried
It can be combined with injectable GHK-Cu for enhanced results
It should not currently be described as an FDA-approved obesity medication
When looking at the percentage of participants that dropped out of the trial due to adverse effects, 2-6% of patients in the cagrilintide group discontinued treatment early while 7% of the participants receiving liraglutide discontinued treatment early, These findings were in comparison to only 3% of test subjects from the placebo group that discontinued treatment due to adverse events [1]
For example, the standard semaglutide (Wegovy) protocol exponentially escalates the dose every 4 weeks 0.25 mg for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg/week by about week 16 (source)
Consult WARNINGS section for additional precautions